D Paquin-Proulx1, C Ching2, I Vujkovic-Cvijin2, D Fadrosh3, L Loh2, Y Huang4, M Somsouk3, S V Lynch3, P W Hunt5, D F Nixon1, D SenGupta2. 1. Department of Microbiology, Immunology and Tropical Medicine, The George Washington University, Washington, District of Columbia, USA. 2. Division of Experimental Medicine, Department of Medicine, University of California, San Francisco, San Francisco, California, USA. 3. Division of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA. 4. Department of Bioengineering and Therapeutic Sciences, School of Pharmacy University of California, San Francisco, California, USA. 5. HIV/AIDS Division, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA.
Abstract
Invariant natural killer T (iNKT) cells are innate-like T cells that respond to lipid antigens presented by CD1d. These immunoregulatory cells have the capacity for rapid cytokine release after antigen recognition and are essential for the activation of multiple arms of the immune response. HIV-1 infection is associated with iNKT cell depletion in the peripheral blood; however, their role in the gastrointestinal-associated lymphoid tissue (GALT) is less well studied. Our results show that iNKT cells are found at a higher frequency in GALT compared with blood, particularly in HIV-1 elite controllers. The capacity of iNKT cells to produce interleukin-4 (IL-4) and IL-10 in the GALT was associated with less immune activation and lower markers of microbial translocation, whereas regulatory T cell frequency showed positive associations with immune activation. We hypothesized that the composition of the microbiota would influence iNKT cell frequency and function. We found positive associations between the abundance of several Bacteroides species and iNKT cell frequency and their capacity to produce IL-4 in the GALT but not in the blood. Overall, our results are consistent with the hypothesis that GALT iNKT cells, influenced by certain bacterial species, may have a key role in regulating immune activation in HIV-1 infection.
Invariant natural killer T (iNKT) cells are innate-like T cells that respond to lipid antigens presented by CD1d. These immunoregulatory cells have the capacity for rapid cytokine release after antigen recognition and are essential for the activation of multiple arms of the immune response. HIV-1 infection is associated with iNKT cell depletion in the peripheral blood; however, their role in the gastrointestinal-associated lymphoid tissue (GALT) is less well studied. Our results show that iNKT cells are found at a higher frequency in GALT compared with blood, particularly in HIV-1 elite controllers. The capacity of iNKT cells to produce interleukin-4 (IL-4) and IL-10 in the GALT was associated with less immune activation and lower markers of microbial translocation, whereas regulatory T cell frequency showed positive associations with immune activation. We hypothesized that the composition of the microbiota would influence iNKT cell frequency and function. We found positive associations between the abundance of several Bacteroides species and iNKT cell frequency and their capacity to produce IL-4 in the GALT but not in the blood. Overall, our results are consistent with the hypothesis that GALT iNKT cells, influenced by certain bacterial species, may have a key role in regulating immune activation in HIV-1 infection.
HIV-1 infection leads to the development of chronic inflammation that
persists even in antiretroviral (ART)-treated individuals with undetectable viral
loads[1,2]. This inflammation is associated with non-HIV
comorbidities, including cardiovascular disease, neurologic disorders, cancers, and
an overall increased mortality. It has become apparent that immune activation is a
better predictor of HIV-1 disease progression than either peripheral blood
CD4+ T-cell count or viral load[3], highlighting the importance of chronic
immune activation. However, distinct pathways of immune activation (innate vs.
adaptive) appear to have differential prognostic capacity, depending on the
cohorts[4]. Importantly,
while ART significantly diminishes immune activation (particularly if initiated
early after infection[5]), levels do
not normalize to those of uninfected individuals. Invariant natural killer T (iNKT)
cells are innate-like T cells that respond to lipid antigens presented on CD1d, an
MHC class I-like molecule expressed on antigen presenting cells (APCs)[6]. iNKT cells are characterized by
their expression of the semi-invariant T cell receptor chain
Vα24-Jα18 preferentially paired to a Vβ11 chain. Upon
stimulation, iNKT cells are capable of rapid production of a vast array of cytokines
and chemokines and are instrumental in orchestrating innate and adaptive immune
response[7]. iNKT cells can
recruit and modulate other immune cells, including natural killer (NK) cells,
dendritic cells (DC), and conventional CD4+ and
CD8+ T cells[8]. Depending on the type of specific interactions between iNKT
cells and DCs, the cytokines secreted by activated iNKT cells may either activate or
suppress adaptive immune responses.Mouse studies have shown that the symbiotic microbiota can impact the
maturation and function of iNKT cells in the mucosa[9,10]. A
sphingolipid produced by the human commensal Bacteroides fragilis
has been shown to bind CD1d and modulate iNKT cells[11]. When compared to specific pathogen
free-mice, germ-free mice have a greater frequency of iNKT cells in intestinal
lamina propria and epithelium, but these cells express lower levels of activation
and produce less cytokines in response to stimulation[12]. Therefore, the gut microbiome influences
the post-thymic maturation of iNKT cells, and intestinal bacterial reconstitution is
a potential strategy for correcting systemic iNKT hypo-responsiveness in individuals
with an altered microbial landscape. Dysbiosis of gut microbiota, particularly
depletion of Bacteroidia members (including Bacteroides fragilis),
has recently been described in the context of untreated HIV-1 infection, and is
associated with markers of systemic immune activation and chronic
inflammation[13].Mouse studies have revealed a role for iNKT cells in the control of viral
infections, but their involvement in viral immunity in humans is less well
characterized[14,15]. Previous studies have shown that iNKT cells
in the peripheral blood are selectively and rapidly depleted in early HIV-1infection[16] and in models
of SIV-infected non-human primates[17]. Some studies reported reduced iNKT proliferation and cytokine
secretion (IFNγ, TNF, and IL-4in response to αGalCer/IL-2/PMA
stimulation in HIV-1 infection, with variable restoration of function on
antiretroviral therapy (ART)[18-20]. The role of iNKT cells in HIV-1
progression, whether defined by viral replication or immune activation is unclear.
Furthermore, HIV-1 has evolved to escape direct recognition of infected cells by iNKT cells (Paquin-Proulx et al, unpublished observation). Given their ability to
produce IL-10 and activate regulatory T cells (Tregs), iNKT cells have the potential
to help control pathologic T cell activation[21]. In the present study, we investigated the role of
peripheral blood and gut iNKT cells in controlling immune activation in HIV-1infection and the consequences of gut microbial dysbiosis on iNKT frequency and
function.
Results
iNKT cells are reduced in the blood but not in the GALT during HIV-1
infection
A total of 23 HIV-1-infected subjects and 10 healthy controls were
enrolled in the study and paired blood and gut-associated lymphoid tissue (GALT)
samples were obtained (Table 1). Thirteen
of the HIV-infected subjects were on ART at the time of sampling, and three of
the ten untreated patients met the definition of viremic controllers (viral load
below 200 copies/ml). Mononuclear cells were isolated from the samples and flow
cytometry was performed. Staining with Vα24, together with PBS57-CD1d
tetramer, was used to identify iNKT cells (Figure
1A). iNKT cells were increased in the GALT compared to the blood
across all subjects (Supplementary figure 1A). As previously reported, iNKT cells were
found at a reduced frequency in the blood of viremic and ART-treated HIV
subjects compared to healthy controls (Figure
1B)[22-24]. There was a trend for increased iNKT
frequency in the ART-treated group compared to the viremic group
(p=0.07). Surprisingly, no change in iNKT cell frequency was observed in
the GALT of viremic and ART-treated HIV-infected individuals compared to healthy
controls (Figure 1C). HIV controllers
appeared to have preserved iNKT cell frequency in the blood and higher frequency
in the GALT compared to all other groups. Next, we investigated the distribution
of the CD4+ subset of iNKT cells as this population has been shown to be
preferentially depleted in the peripheral blood during HIV infection[22,23]. No significant differences were observed between
HIV-infected individuals and controls (Figure
1D) and between the viremic and ART-treated groups (Supplementary Figure 1B and C) both
in the blood and in GALT. However, HIV-infected subjects had a significantly
increased proportion of CD4+ iNKT cells in GALT compared to the blood
(Figure 1D). Our results confirm the
loss of iNKT cell in the blood of HIV-infected individuals that has been
reported by several studies before and suggest for the first time, that iNKT
cells may be preserved in the GALT in these patients.
Table 1
Subjects demographics
Gender
Age
CD4 count
Viral load
Duration of infection (years)
Time on ART (total years)
Healthy (n=10)
9M, 1F
32.5 (23-59)
828 (538-1,173)
HIV (n=23)
viremic (n=7)
5M, 1M to F, 1F
46 (31-61)
458 (257-887)
13,187 (1,102-305,178)
6.0 (0-23)
0 (0-0.97)
ART (n=13)
12M, 1F
54 (32-66)
616 (374-1,023)
undectable
24.5 (1-34)
7.9 (0.9-19.6)
Controllers
(n=3)
2M, 1F
46 (25-50)
573 (393-900)
undectable (undectable-141)
15 (3-27)
0 (0-0.56)
Figure 1
Frequency of iNKT cells in the blood and GALT
Representative gating strategy, iNKT cells were identified based on Vα24
and PBS57-CD1d tetramer positive stainings (A). Frequency of iNKT cells in the
blood (B) and in the GALT (C) for healthy controls (n=10), viremic
(n=7), ART-treated (n=13), and viremic controllers HIV-infected
subjects (n=3). Frequency of iNKT cells expressing CD4 in the blood and
GALT of healthy controls (blood n=8 and GALT n=9) and
HIV-infected subjects (blood n=22 and GALT n=17) (D). *
indicates p < 0.05 and ** indicates p <
0.01.
iNKT cells in the GALT of HIV-infected individuals have a Th2 cytokine
profile
Previous studies demonstrated that cytokine production by iNKT in the
blood of HIV-infected subjects is impaired[19]. However, cytokine production by iNKT cells in the GALT
may be more relevant during HIV-1 disease progression. To assess the functional
potential of iNKT cells, PBMC and rectal mononuclear cells (RMC) were stimulated
with PMA and ionomycin and the production of IFNγ, TNF, IL-4 and IL-10
was evaluated by flow cytometry (Figure
2A). No differences were observed in cytokine production by iNKT cells in
the blood and GALT of HIV-individuals compared to healthy controls. The majority
of iNKT cells in the blood of healthy controls produced IFNγ and TNF
while the frequencies of IL-4 and IL-10 producing iNKT were low (Figure 2B, C, D, and E). However, we observed a trend
for a lower frequency of IFNγ+ and TNF+ iNKT cells in
the GALT of healthy individuals compared to the blood. This difference was even
more marked in the HIV-infected subjects. The percentage of iNKT in the GALT
producing IL-4 and IL-10 varied greatly, ranging from undetectable to
100%. There was a trend for higher IL-4+ (p=0.06) and
IL-10+ (p=0.06) iNKT cells in the GALT compared to the blood for
HIV-infected individuals only. Our results suggest that a greater proportion of
GALT iNKT cells in HIV-subjects have a Th2 cytokine profile compared to the
blood.
Figure 2
Cytokine production by iNKT cells in the blood and GALT
Cells were stimulated with PMA and Ionomycin before intracellular staining for
cytokines. The gates were set using unstimulated controls, representative
staining for IFNγ, TNF, IL-4 and IL-10 (A). Percentage of iNKT cells
producing IFNγ (B, controls: blood n=8, GALT n=9 and
HIV-infected subjects: blood n=16, GALT n=15), TNF (C, controls:
blood n=8, GALT n=9 and HIV-infected subjects: blood
n=16, GALT n=13), IL-4 (D, controls: blood and GALT n= 7
and HIV-infected subjects: blood and GALT n=13) and IL-10 (E, controls:
blood and GALT n= 7 and HIV-infected subjects: blood and GALT n=
15). * indicates p < 0.05 and ** indicates p
< 0.01.
Production of IL-4 and IL-10 by iNKT is associated with lower immune
activation in the blood of HIV-infected subjects
Next, we evaluated immune activation of CD4+ and
CD8+ T cells in the blood and in the GALT by measuring
co-expression of CD38 and HLA-DR. In healthy controls, we found a trend towards
increased activation of CD4+ T cells in the GALT compared to
the blood (Figure 3A, p=0.08).
Significantly higher levels of CD38 and HLA-DR co-expression were found on
CD4+ and CD8+ T cells in the GALT of
HIV-infected individuals when compared to paired blood samples (Figure 3A and B). A non-significant trend for greater
cellular activation in the blood was observed when comparing HIV-infected
subjects to controls. However, HIV-infected individuals had significantly
increased activation of both CD4+ and CD8+
T cells in the GALT compared to healthy controls. Single expression of CD38 was
also analyzed (Supplementary
Figure 3A and B). iNKT cells are believed to have regulatory
functions, which are in part mediated by their capacity to produce
cytokines[7]. Therefore,
we investigated if there was any association between cytokine production by iNKT
cells and immune activation in HIV-infected subjects. We found no associations
between immune activation in the GALT and iNKT cell cytokine production (data
not shown). However, IL-10 production by iNKT cells in the blood was associated
with lower CD4+ and CD8+ T cell activation
in the blood (Figure 3C and D).
Furthermore, IL-10 and IL-4 production by GALT iNKT cells were respectively
associated with lower CD4+ and CD8+ T cell
immune activation in the blood (Figure 3E and
F). HIV-infected subjects were then grouped according to the capacity
of iNKT cells to produce IL-10 and the levels of immune activation were
compared. Subjects with GALT iNKT cells producing IL-10 had significantly lower
frequencies of activated peripheral CD4+ T cells (Supplementary Figure 2 A)
and subjects with blood iNKT cells producing IL-10 showed a trend for lower
levels of activated peripheral CD4+ and
CD8+ T cells (Supplementary Figure 2 B and C). In
addition, we analyzed CD38 single expression and its associations with iNKT cell
cytokine production. CD38 expression was inversely associated with IL-4 and
IL-10 production by GALT iNKT cells and IL-10 production by blood iNKT cells
(Supplementary Figure
3). These results suggest a role for GALT iNKT cells in dampening the
pathological peripheral immune activation in HIV-1 infection.
Figure 3
CD4+ and CD8+ T cell activation in the
blood and GALT and associations with iNKT cell cytokine production
Co-expression of CD38 and HLA-DR on CD4+ T cells (A) and
CD8+ T cells (B) in the blood and GALT of controls
(n=7) and HIV-infected subjects (n=18). Associations between
IL-10+ iNKT cells in the blood and
CD38+HLA-DR+ CD4+
(C) and CD8+ (D) T cells of HIV-infected subjects.
Associations between IL-10+ and IL-4+ iNKT
cells in the GALT of HIV-infected subjects and
CD38+HLA-DR+ CD4+
(E) and CD8+ (F) T cells respectively. * indicates p
< 0.05 and ** indicates p < 0.01.
In addition to iNKT cells, Tregs are also known to have an important role
in modulating immune activation[25]. Therefore, we analyzed Tregs (defined as
CD3+, CD4+, CD25+
and Foxp3+) frequencies in peripheral blood and GALT of
HIV-infected individuals. Similar frequencies of Tregs across groups were
observed in the blood and in the GALT (Supplementary Figure 4A) and no
difference in the frequency of Tregs in the blood compared to the GALT was
observed for controls and HIV-infected individuals. We observed a positive
association between Tregs frequency in the GALT and CD4+ and
CD8+ T cell activation in the GALT of HIV-infected
individuals (Supplementary
Figure 4B and C). No associations were found between Tregs and iNKT
cell frequency or function (data not shown).
Cytokine production by GALT iNKT cells is associated with lower microbial
translocation
Damage to the integrity of the gut epithelial barrier by HIV-1 infection
has been reported to lead to the presence of microbial products in the
circulation, often referred to as microbial translocation (MT). MT has been
associated with the pathologic immune activation that is characteristic of HIV-1
disease[26]. The
kynurenine (Kyn) pathway of tryptophan (Trp) catabolism has been demonstrated to
be dysregulated in HIV-1 infection, leading to an elevated Kyn/Trp ratio in the
blood[27]. This
dysregulation is reported to be associated with changes in the composition of
the microbiome of HIV-infected individuals and with established markers of
disease progression such as IL-6[13]. We postulated that the immunoregulatory activity of GALT
iNKT cells may limit disturbance to the gut barrier and therefore lower immune
activation by reducing MT. For this purpose, we measured the concentration of
soluble CD14 (sCD14) and LPS-binding protein (LBP) in the plasma as they have
been shown to be indirect markers of MT[26,28]. We also
measured intestinal fatty acid-binding protein 2 (I-FABP2, a marker of gut
damage[29]), IL-6 and
the Kyn/Trp ratio. As expected, HIV-infected subjects had significantly elevated
levels of sCD14, LBP, and I-FABP2 (Figure 4A, B,
and C), suggesting gut epithelial barrier dysfunction and MT. The
Kyn/Trp ratio was also elevated in HIV-infected individuals (Figure 4D) as well as the levels of IL-6 (Supplementary Figure 5).
We then looked for relationships between all of the above parameters and iNKT
frequency or function. The capacity of peripheral iNKT cells to produce IL-4 was
positively associated with plasma levels of sCD14 and there was a trend for an
inverse association between the capacity of intestinal iNKT cells to produce
IL-10 and the levels of sCD14 (Figure 4E and
F). iNKT cell production of IL-4 and TNF-α in the GALT showed
negative associations with the levels of LBP (Figure 4G and H). Finally, IL-4 production by peripheral iNKT cells
was associated with elevated Kyn/Trp ratios (Figure 4I). Additionally, HIV-infected subjects were grouped
according to capacity of iNKT cells to produce IL-4 or IL-10. We observed that
individuals in the group with higher production of IL-4 had lower levels of
sCD14 (Supplementary Figure
6). Together, our results show that a higher capacity to produce
cytokines by iNKT in the GALT is associated with lower markers of MT, suggesting
a role for GALT iNKT cells in modulating this pathological process in HIV-1infection.
Figure 4
Markers of microbial translocation and associations with iNKT cell cytokine
production
The levels of sCD14 (A), LBP (B), I-FABP2 (C), and Kyn/Trp ratio (D) were
determined in the serum of healthy controls (n=9) and HIV-infected
subjects (n=23). Associations between the levels of sCD14 in
HIV-infected subjects and IL4+ iNKT cells in the blood (E)
and IL10+ iNKT cells in the GALT (F). Associations between
LBP levels in the serum of HIV-infected subjects and IL4+ (G)
and TNF+ (H) iNKT cells in the GALT. Association between
Kyn/Trp ratio in HIV-infected subjects and IL4+ iNKT cells in
the blood (I). * indicates p < 0.05 and **
indicates p < 0.01.
Bacteroides are associated with iNKT frequency and IL-4 production in the
GALT
The composition of the bacterial gut microbiota of untreated
HIV-infected subjects is distinct from that of healthy individuals, with
ART-treated patients having an intermediate change in the microbiome
profile[30]. One of the
genera significantly depleted in HIV-infected individuals is
Bacteroides. We confirmed that Bacteroides
were reduced in ART-treated HIV-infected subjects in our study (Figure 5A). Next, we performed an unbiased analysis of
all gut-resident operational taxonomic units (OTUs) abundances compared to GALT
iNKT cell frequency in ART-treated subjects and found that negative correlations
existed between GALT iNKT cell frequency and OTUs in the
Prevotella genus (Benjamini-Hochberg Q value <
0.15, Supplementary
file), a genus that has been shown to be increased in abundance in
HIV-infected subject gut microbiomes and associated with elevated mucosal immune
activation[31]. Given
that Bacteroides fragilis expresses a glycolipid that can
activate human iNKT cells[11],
we investigated whether the abundance of (OTUs) within the
Bacteroides genus was associated with frequencies of iNKT
cells in both peripheral blood and GALT within ART-treated HIV-infected
subjects, all study subjects combined, and uninfected subjects only (Figure 5B and C, Supplementary file). Fewer OTUs
reached P<0.10 for comparisons to peripheral blood as opposed to GALT
iNKT frequencies, and no trends were consistent across all subject groupings for
comparisons to peripheral blood. However, when comparing OTU abundances to GALT
iNKT frequencies, consistent positive associations were found between several
Bacteroides OTUs and iNKT frequencies across subject
groups. Finally, we looked for associations between Bacteroides
OTUs and cytokine production by iNKT cells. We found a positive association
between specific Bacteroides OTUs and the capacity of GALT iNKT
cells to produce IL-4 (Figure 5D, Supplementary file),
though these observations exhibited Benjamini-Hochberg false discovery rate Q
values > 0.70. These results suggest that loss of the
Bacteroides genus in HIV-infected individuals could
influence both the frequency and function of iNKT cells in the gut.
Figure 5
Change in microbiota in HIV-infected individuals and associations with iNKT
frequency and function
Wilcoxon rank-sum tests were performed comparing gut mucosal OTU abundances
between HIV-infected subjects undergoing ART and uninfected subjects. OTUs with
p < 0.15 are shown including taxonomic families to which each OTU
belongs. Wilcoxon V statistics (y-axis) provide non-parametric
enrichment/depletion information, and unadjusted P values are depicted by point
sizes (A). Abundance of all detected OTUs within the
Bacteroides genus were compared to blood iNKT cell percent
abundances for three subject groups (ART HIV-infected, uninfected, and all
subjects combined). Spearman rho values depict directionality of correlation,
and all OTUs with p < 0.10 shown (B). Abundance of all
Bacteroides OTUs were compared to GALT iNKT cell percent
abundances for the same subject groups (C, p < 0.10 shown). Spearman
correlations were performed comparing all Bacteroides OTU
relative abundances and proportions of IL-4+ GALT iNKT cells
following PMA and ionomycin stimulation (D, p < 0.10 shown).
Discussion
Several studies have examined the frequency and function of peripheral blood
iNKT cells in HIV-1 infection but limited information is available for the GALT, an
important target in HIV-1 pathogenesis. We found that iNKT cells were depleted in
the blood but not in the GALT of HIV-infected subjects and that GALT iNKT cells
consisted of an increased proportion of the CD4+ subset. This is
in contrast to a previous study that reported that CD4+ iNKT
cells are lost in the gut of HIV-1-infected individuals[32]. The discrepancy between our results and
those of Ibarrondo et al. could be explained by important
differences in the HIV-1 cohorts and the methods used to identify iNKT cells. The
majority of our HIV-1-infected individuals had an undetectable viral load
(ART-suppressed or controllers) and we used a CD1d tetramer to identify iNKT cells
while the cohort of Ibarrondo et al. consisted exclusively of
untreated subjects and iNKT cells were identified using antibodies against the
invariant TCR. Altogether, this would suggest that viral suppression prevents the
depletion of the CD4+ subset of iNKT cells in the GALT. Although
based on a small number of subjects, our results suggest that HIV-1 elite
controllers maintain normal iNKT cell frequency in the blood and have high levels of
iNKT cells in the GALT. Further studies enrolling more controllers will be required
to confirm the validity of these results.CD4+ iNKT are known to produce more Th2 cytokines than
the CD4- subsets[33-35]. Therefore, given our finding of
higher percentages of CD4+ iNKT in the gut as compared to blood
in HIV-infected subjects, it is not surprising that we observed more production of
IL-4 and IL-10, two Th2 cytokines, and less IFNγ and TNFα by iNKT
cells in the GALT compared to the blood. Our results suggest that iNKT cells can
regulate the pathologic chronic immune activation in HIV-1 infection by their
production of IL-4 and IL-10 in the GALT as well as IL-10 in the blood. We could not
detect iNKT cell production of IL-10 by a significant proportion of HIV-infected
individuals, suggesting that they could be separated in two groups based on the
capacity of iNKT cells to produce IL-10. However, this could be due to the detection
limit of the assay. Further studies with more subjects in each group are required to
resolve this matter. Our findings are consistent with the model proposed by Rout
et al who have shown that sooty mangabeys, natural hosts of SIV
that do not progress to AIDS, exhibit a preservation of iNKT cell frequency and
function after SIV infection. They have thus suggested that iNKT cell dysfunction
has a role in AIDS pathogenesis[36].
MT has been proposed as a major component driving immune activation in HIV-infected
individuals. We found that production of IL-4, IL-10 and TNF by iNKT cells in the
GALT, but not in the blood, were associated with lower MT as measured by sCD14 and
LBP, suggesting that iNKT cell production of IL-10 in the blood could have a
localized effect on immune activation while production of the same cytokine in the
GALT could have a more generalized effect by reducing MT. In contrast, the frequency
of Tregs in the GALT was positively associated with CD4+ and
CD8+ T cell activation in the GALT. We saw no association
between Tregs and markers of MT, suggesting a specific role for iNKT cells. How
production of IL-4, IL-10 and TNF by GALT iNKT cells contributes to reduced MT
remains to be determined. It is a likely possibility that the ability of iNKT cells
to interact with APCs to shape the adaptive immune response may be involved.
Moreover, mice lacking IL-10 have been shown to have increased gut permeability
caused by an excessive Th1 response against enteric bacteria[37]. On the other hand, the positive
associations between IL-4 production by peripheral iNKT and Kyn/Trp ratio and sCD14
might represent in part their response to MT.To our knowledge, this is the first study looking at the influence of the
microbiome on iNKT cell frequency and function in humans. A study performed in mice
showed that a sphingolipid derived from Bacteroides fragilis can
inhibit iNKT cell activation and that Bacteroides fragilis
colonization reduces the frequency of iNKT cells in the colon but not in other
organs or in the blood[10]. A
different group reported that Bacteroides fragilis produced a
sphingolipid that can activate iNKT cells[11]. In our hands, multiple Bacteroides OTUs
exhibited positive associations with GALT iNKT cells and only one OTU presented a
negative association in HIV-infected subjects (with the later association not being
present in uninfected subjects). This would suggest that
Bacteroides produce an antigen that can activate and expand
iNKT cells in the GALT. The reported greater abundance of
Bacteroides in HIV elite controllers compared to viremic
patients[38] could therefore
contribute to the higher frequency of iNKT in the GALT of elite controllers in our
study. Mouse studies have shown that animals kept in germ-free conditions have lower
IFNγ, TNF and IL-4 production by iNKT cells following stimulation with
α-Gal-Cer[12], but
the bacteria responsible for the functional maturation of iNKT cells were not
identified. In this study, we have found a positive association between
Bacteroides and IL-4 production by GALT iNKT cells. While fetal
human iNKT cells have been reported to mature and acquire function in the small
intestine before colonization by the normal microbiota[39], our results are consistent with the
hypothesis that in adults the normal microbiota may provide signals that support
GALT iNKT cell frequency and functionality. These findings would be strengthened by
further study in larger human cohorts. Vα24- cells specifically
binding to α-Gal-Cer loaded CD1d tetramer have been detected in PBMC
following in vitro expansion[40]. However, the limited amount of GALT material obtained in
our study did not allow us to study this population of NKT cells.Based on our results, we propose a model where iNKT cells in the GALT have
an important role in limiting MT and chronic pathologic immune activation in HIV-1infection. This role of GALT iNKT is influenced by the composition of the gut
microbiota, with loss of the Bacteroides genus in HIV-infected
individuals possibly affecting both iNKT frequency and function. This suggests that
strategies boosting GALT iNKT cells could reduce the MT and persistent immune
activation that are important factors in the morbidity caused by HIV-1.
Materials and Methods
Study subjects
PBMCs and GALT samples were obtained from participants in the San
Francisco-based HIV-1-infected SCOPE cohort. Samples from HIV-1-seronegative
controls were obtained from healthy volunteers. The study was approved by the
local Institutional Review Board (University of California San Francisco
Committee on Human Research), and individuals gave written informed consent.
Samples were obtained from the following numbers and categories of
HIV-1-infected individuals: 3 untreated virologic “controllers”
(viral load, <200 HIV-1 copies/ml), 13 HAART-suppressed patients (viral
load, <50 copies/ml), and 7 untreated “virologic
noncontrollers” (viral load, >1,000 copies/ml). All had
CD4+ T cell counts of >250 cells/mm[3]. See Table 1 for baseline subject characteristics.
Blood and GALT samples
5 ml of blood was collected in BD Vacutainer EDTA coated tubes for PBMC
and plasma isolation purposes. After centrifuging at 400g for 10 min without
braking, the plasma layer was removed and frozen at -80°C for ELISA
quantification. The cellular fraction from the first spin was used to isolate
PBMC by centrifugation over a ficoll-paque (GE Healthcare, Uppsala, Sweden)
layer at 800g for 25 min without braking. The PBMC layer was then removed and
washed twice in RPMI with L-glutamine, Penicillin/Streptomycin, Hepes, and
10% Fetal bovine serum (referred now on as R-10) at 400g for 10 min with
braking. GALT from rectosigmoid biopsy specimens were placed on a shaking
incubator at 37°C with a digestion mix of RPMI with
+L-glutamine, Hepes, Penicillin/Streptomycin, and Collagenase Type II
(0.25mg/ml) (Sigma-Aldrich, St. Louis, MO, USA). After one digestion of 30
minutes, sample was strained through a 70 uM cell strainer and washed through
with cold R-10. Undigested biopsies were transferred into the collagenase
digestion mix for repeat digestion of 30 min. Strained and digested biopsies
were washed in R-10 and spun down at 700g for 6 minutes at 4°C to
isolate the RMC. PBMCs and RMCs were then re-suspended and counted using Guava
Viacount (Millipore, Brillerica, MA, USA) on the Accuri C6 (BD Biosciences, San
Jose, CA, USA).
Flow cytometry and mAbs
For surface staining, cells were stained with surface markers for 30
min on ice and washed twice with FACS buffer (PBS with 2% FBS and 2
mM EDTA buffer). After, cells were fixed and permeabilized with Fix/Perm
buffer (BD Biosciences) for 20 min on ice, washed twice with BD Perm/Wash,
and stained with the intracellular antibodies for 60 min on ice. For PoxP3
staining, cells were fixed and permeabilized with Fix/Perm Buffer
(eBiosciences, San Diego, CA, USA) for 60 min on ice, washed twice with
Perm/Wash buffer (eBiosciences) and stained with intracellular antibodies
for 60 min on ice. Subsequently, the cells were washed twice with the
respective Perm/Wash buffer and kept in 2% paraformaldehyde.
Antibodies used: PBS57-CD1d tet APC (kindly donated by NIH tetramer resource
facility), Vα24 FITC, and CD3 ECD were from Beckman Coulter
(Fullerton, CA), CD4 Qdot655, CD8 Qdot 605, and the viability marker AmCyan
were from Life Technologies (Carlsbad CA, USA), CD25APC, CD38 PE, HLA-DR
PerCP, IFNγ V450, TNF Alexa700, IL-10 PE, and IL-4 PE-Cy7 were all
from BD bioscience. Data were acquired on a BD LSRFortessa instrument (BD
Biosciences) and analyzed using FlowJo Version 9.8.5 software (TreeStar,
Ashland, OR, USA).
ELISA
Il-6, sCD14, LBP, and FABP-2 levels were detected in plasma isolated
from peripheral blood with a commercially available enzyme-linked
immunosorbant assay (all from R&D Systems, Minneapolis, MN, USA) and
performed according to the standard protocol. For sCD14 and IL-6,
commercially available quality controls (R&D Systems) were also
performed to ensure accurate detection of the kits.
Microbiome sample processing and analysis
DNA was extracted from gut biopsy samples using the AllPrep DNA/RNA
Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's
recommendations. Each DNA sample was PCR amplified in triplicate using
primer pairs that targeted the V4 hypervariable region of the 16S rRNA gene,
contained a unique barcode sequence to enable demultiplexing of pooled
samples, and contained an adapter sequence that enables the amplicon to bind
to the MiSeq flow cell. Successful amplicons were pooled in approximately
equal molar concentrations and sequenced on the Illumina MiSeq platform.
Paired sequencing reads were quality filtered and demultiplexed using the
QIIME software package. Briefly, assembled sequencing read pairs were binned
into OTUs (operational taxonomic units using a 97% similarity to the
Greengenes database) and reads that either did not cluster to the Greengenes
database or that were chimeric were removed from subsequent analyses. OTUs
that had a cumulative read count across all samples of less than
0.001% of the total reads were removed from downstream analysis.
Sample read numbers were rarefied to the read number of the lowest sample
after processing (94,780) resulting in a rarefied OTU table. OTU abundances
were compared between uninfected and ART-treated HIV-infected subjects using
a custom R script in conjunction with the “exactRankTests”
package. Spearman correlations were performed using the
“Hmisc” R package using a custom script. Data visualizations
were performed using the R package “ggplot2”.
Tryptophan metabolism
Liquid chromatography–tandem mass spectrometry was used to
assess kynurenine and tryptophan levels as previously described[41].
Statistical analysis
All statistical analysis was performed using Graph Pad Prism version
6.0f for Mac OSX (GraphPad Software, La Jolla, CA). Groups where compared
using the Mann-Whitney test, paired blood and GALT samples were compared
using Wilcoxon marched-pairs signed rank test. Associations between groups
were determined by Spearman's rank correlation. P values <
0.05 were considered statistically significant.Supplementary Figure 1. Frequency of CD4
Percentage of iNKT cells in the blood and the GALT of all subjects (A,
n=33). Percentage of the CD4+ subset of iNKT
cells in the blood (B, controls n=8, HIV-untreated n=6,
HIV-ART treated n=13, and HIV-controllers n=3) and GALT (C,
controls n=9, HIV-untreated n=5, HIV-ART treated
n=9, and HIV-controllers n=3).
*** indicates p < 0.001.Supplementary Figure 2. CD4 T cell immune activation in
HIV-infected individuals with or without IL-10 production by GALT iNKT
cells. Comparison between the levels of
CD38+HLA-DR+
CD4+ T cells in the blood of HIV-infected subjects
with (n=8) or without (n=7) IL-10 production by GALT iNKT
cells (A). Comparison between the levels of
CD38+HLA-DR+
CD4+ (B) and CD8+ (C) T cells in
the blood of HIV-infected subjects with (n=8) or without
(n=7) IL-10 production by blood iNKT cells.
*** indicates p < 0.001.Supplementary Figure 3. IL-4 and IL-10 production by iNKT cell
are associated with lower CD38 levels. Expression of CD38 on
CD4+ T cells (A) and CD8+ T cells
(B) in the blood and GALT of controls (n= 7) and HIV-infected
subjects (n=18). Associations between IL-4+ iNKT
cells in the GALT and CD38+ expression on
CD4+ T cells in the GALT (C) and
CD8+ T cells in the blood (D) and GALT (E) of
HIV-infected subjects. Associations between IL-10+ iNKT
cells in the GALT and CD38 expression by CD4+ T cells in
the blood (F) of HIV-infected subjects. Associations between
IL-10+ iNKT cells in the blood and CD38 expression by
CD4+ T cells in the GALT (G), CD38 expression by
CD8+ T cells in the blood (H) and GALT (I) of
HIV-infected subjects. Comparison between the expression of CD38 by
CD4+ T cells in the blood of HIV-infected subjects
with (n=6) or without (n=7) IL-10 production by GALT iNKT
cells (J). Comparison between the expression of CD38 by
CD4+ T cells in the GALT (K), CD8+
T cells in the blood (L) and GALT (M) of HIV-infected subjects with
(n=6) or without (n=7) IL-10 production by blood iNKT cells.
* indicates p < 0.05 and ***
indicates p < 0.001.Supplementary Figure 4. Frequency of Tregs in the blood and
GALT of HIV-infected individuals. Tregs were defined as
CD4+CD25+Foxp3+
T cells and their frequency was measured in the blood and GALT of healthy
controls (n=8) and HIV-infected subjects (n=22) (A).
Association between CD38+HLA-DR+
CD4+ T cells and Tregs frequency in the GALT of
HIV-infected subjects (B). Association between CD38+
CD8+ T cells and Tregs frequency in the GALT of
HIV-infected subjects (C).Supplementary Figure 5. IL-6 levels in HIV-infected
individuals. IL-6 was measured by ELISA in the plasma of healthy
controls (n=9) and HIV-infected subjects (n=22). *
indicates p < 0.05.Supplementary Figure 6. Markers of microbial translocation in
HIV-infected individuals with or without production of IL-4 or IL-10 by
iNKT cells. Comparison between the levels of sCD14 in the plasma
of HIV-infected subjects with iNKT cells producing IL-4 >10%
(n=6) or <10% (n=9) (A). Comparison between
the levels of sCD14 in the plasma of HIV-infected subjects with
(n=8) or without (n=7) IL-10 production by GALT iNKT cells
(B). Comparison between the Kyn/Trp ratio in the plasma of HIV-infected
subjects with iNKT cells producing IL-4 >10% (n=6)
or <10% (n=9) (C). ** indicates p
< 0.01.
Authors: Dale I Godfrey; Daniel G Pellicci; Onisha Patel; Lars Kjer-Nielsen; James McCluskey; Jamie Rossjohn Journal: Semin Immunol Date: 2009-11-28 Impact factor: 11.130
Authors: Torsten Olszak; Dingding An; Sebastian Zeissig; Miguel Pinilla Vera; Julia Richter; Andre Franke; Jonathan N Glickman; Reiner Siebert; Rebecca M Baron; Dennis L Kasper; Richard S Blumberg Journal: Science Date: 2012-03-22 Impact factor: 47.728
Authors: A C Chan; E Leeansyah; A Cochrane; Y d'Udekem d'Acoz; D Mittag; L C Harrison; D I Godfrey; S P Berzins Journal: Clin Exp Immunol Date: 2013-04 Impact factor: 4.330
Authors: F J Ibarrondo; S B Wilson; L E Hultin; R Shih; M A Hausner; P M Hultin; P A Anton; B D Jamieson; O O Yang Journal: Mucosal Immunol Date: 2012-11-14 Impact factor: 7.313
Authors: Vivek Jain; Wendy Hartogensis; Peter Bacchetti; Peter W Hunt; Hiroyu Hatano; Elizabeth Sinclair; Lorrie Epling; Tzong-Hae Lee; Michael P Busch; Joseph M McCune; Christopher D Pilcher; Frederick M Hecht; Steven G Deeks Journal: J Infect Dis Date: 2013-07-12 Impact factor: 5.226
Authors: Caroline S Fernandez; Angela C Chan; Konstantinos Kyparissoudis; Robert De Rose; Dale I Godfrey; Stephen J Kent Journal: J Virol Date: 2008-12-03 Impact factor: 5.103
Authors: Laura C Wieland Brown; Cristina Penaranda; Purna C Kashyap; Brianna B Williams; Jon Clardy; Mitchell Kronenberg; Justin L Sonnenburg; Laurie E Comstock; Jeffrey A Bluestone; Michael A Fischbach Journal: PLoS Biol Date: 2013-07-16 Impact factor: 8.029
Authors: Aline Machiavelli; Rubens T Delgado Duarte; Maria M de Souza Pires; Carlos R Zárate-Bladés; Aguinaldo R Pinto Journal: Gut Microbes Date: 2019-01-18
Authors: Charles Kyriakos Vorkas; Matthew F Wipperman; Kelin Li; James Bean; Shakti K Bhattarai; Matthew Adamow; Phillip Wong; Jeffrey Aubé; Marc Antoine Jean Juste; Vanni Bucci; Daniel W Fitzgerald; Michael S Glickman Journal: JCI Insight Date: 2018-10-04
Authors: Dominic Paquin-Proulx; Anna Gibbs; Susanna M Bächle; Antonio Checa; Andrea Introini; Edwin Leeansyah; Craig E Wheelock; Douglas F Nixon; Kristina Broliden; Annelie Tjernlund; Markus Moll; Johan K Sandberg Journal: J Immunol Date: 2016-08-01 Impact factor: 5.422
Authors: Sofia Cussotto; Conall R Strain; Fiona Fouhy; Ronan G Strain; Veronica L Peterson; Gerard Clarke; Catherine Stanton; Timothy G Dinan; John F Cryan Journal: Psychopharmacology (Berl) Date: 2018-08-28 Impact factor: 4.530
Authors: Josué Pérez-Santiago; María J Marquine; Debralee Cookson; Rafael Giraud-Colón; Robert K Heaton; Igor Grant; Ronald J Ellis; Scott L Letendre; Scott N Peterson Journal: J Neurovirol Date: 2021-03-02 Impact factor: 2.643
Authors: Carolyn Yanavich; Hugo Perazzo; Fan Li; Nicole Tobin; David Lee; Sara Zabih; Michelle Morata; Cristiane Almeida; Valdilea G Veloso; Beatriz Grinsztejn; Grace M Aldrovandi Journal: AIDS Date: 2022-01-01 Impact factor: 4.632